Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Restricted access

Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with hematologic disorders with the goal of re-establishing normal hematopoietic and immune function. HCT is classified as autologous or allogeneic based on the origin of hematopoietic cells. Autologous HCT uses the patient’s own cells while allogeneic HCT uses hematopoietic cells from a human leukocyte antigen-compatible donor. Allogeneic HCT is a potentially curative treatment option for patients with certain types of hematologic malignancies, and autologous HCT is primarily used to support patients undergoing high-dose chemotherapy. Advances in HCT methods and supportive care in recent decades have led to improved survival after HCT; however, disease relapse and posttransplant complications still commonly occur in both autologous and allogeneic HCT recipients. Allogeneic HCT recipients may also develop acute and/or chronic graft-versus-host disease (GVHD), which results in immune-mediated cellular injury of several organs. The NCCN Guidelines for Hematopoietic Cell Transplantation focus on recommendations for pretransplant recipient evaluation and the management of GVHD in adult patients with malignant disease.

Individual Disclosures for the NCCN Hematopoietic Cell Transplantation Panel

TU1

View associated content

  • 1.

    Khaddour K, Mewawalla P. Hematopoietic stem cell transplantation. Treasure Island, FL: StatPearls; 2019.

  • 2.

    Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:18131826.

  • 3.

    Niederwieser D, Baldomero H, Szer J, . Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 2016;51:778785.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    D’Souza A, Fretham C. CIBMTR Summary Slides: Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT). Accessed April 1, 2020. Available at: https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx

  • 5.

    Majhail NS, Farnia SH, Carpenter PA, . Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21:18631869.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Hosing C. Hematopoietic stem cell mobilization with G-CSF. Methods Mol Biol 2012;904:3747.

  • 7.

    Bensinger WI, Martin PJ, Storer B, . Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175181.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Anasetti C, Logan BR, Lee SJ, . Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367:14871496.

  • 9.

    Lee SJ, Logan B, Westervelt P, . Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol 2016;2:15831589.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Luznik L, O’Donnell PV, Symons HJ, . HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641650.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    McDonald GB, Sandmaier BM, Mielcarek M, . Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts. Ann Intern Med 2020;172:229239.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Majhail NS, Rizzo JD, Lee SJ, . Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:348371.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Jim HS, Syrjala KL, Rizzo D. Supportive care of hematopoietic cell transplant patients. Biol Blood Marrow Transplant 2012;18(1, Suppl)S12S16.

  • 14.

    Servais S, Porcher R, Xhaard A, . Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors. Haematologica 2014;99:519526.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Giebel S, Labopin M, Socié G, . Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 2017;102:139149.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Ribera JM. Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how. Haematologica 2011;96:10831086.

  • 17.

    Trajkovska I, Georgievski B, Cevreska L, . Early and late complications in patients with allogeneic transplantation of hematopoietic stem cell. Open Access Maced J Med Sci 2017;5:340343.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Bacigalupo A, Sormani MP, Lamparelli T, . Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica 2004;89:12381247.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Gooley TA, Chien JW, Pergam SA, . Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:20912101.

  • 20.

    Tanaka Y, Kurosawa S, Tajima K, . Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2016;51:553559.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Wingard JR, Majhail NS, Brazauskas R, . Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011;29:22302239.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Marchesi F, Pimpinelli F, Di Domenico EG, . Association between CMV and invasive fungal infections after autologous stem cell transplant in lymphoproliferative malignancies: opportunistic partnership or cause-effect relationship? Int J Mol Sci 2019;20:1373.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Jantunen E, Itälä M, Lehtinen T, . Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol 2006;76:245250.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    U.S. National Library of Medicine-Key MEDLINE® Indicators.

  • 25.

    Palumbo A, Cavallo F, Gay F, . Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371:895905.

  • 26.

    Child JA, Morgan GJ, Davies FE, . High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:18751883.

  • 27.

    Fermand JP, Katsahian S, Divine M, . High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:92279233.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Attal M, Harousseau JL, Stoppa AM, . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996;335:9197.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Shah N, Callander N, Ganguly S, . Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21:11551166.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Schmitz N, Pfistner B, Sextro M, . Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002;359:20652071.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Perales MA, Ceberio I, Armand P, . Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21:971983.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Philip T, Guglielmi C, Hagenbeek A, . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:15401545.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Oliansky DM, Czuczman M, Fisher RI, . The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011;17:2047.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Oliansky DM, Gordon LI, King J, . The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010;16:443468.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Einhorn LH, Williams SD, Chamness A, . High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007;357:340348.

  • 36.

    Hamid AA, Markt SC, Vicier C, . Autologous stem-cell transplantation outcomes for relapsed metastatic germ-cell tumors in the modern era. Clin Genitourin Cancer 2019;17:5864.e1.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Feldman DR, Sheinfeld J, Bajorin DF, . TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010;28:17061713.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Kilari D, D’Souza A, Fraser R, . Autologous hematopoietic stem cell transplantation for male germ cell tumors: improved outcomes over 3 decades. Biol Blood Marrow Transplant 2019;25:10991106.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Dunkel IJ, Gardner SL, Garvin JH, Jr., . High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro-oncol 2010;12:297303.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Illerhaus G, Müller F, Feuerhake F, . High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008;93:147148.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Kasenda B, Ihorst G, Schroers R, . High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia 2017;31:26232629.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42.

    DeFilipp Z, Li S, El-Jawahri A, . High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer 2017;123:30733079.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Soussain C, Hoang-Xuan K, Taillandier L, . Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol 2008;26:25122518.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    De Rosa L, Lalle M, Pandolfi A, . Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin’s lymphoma in first complete remission. Ann Hematol 2002;81:575581.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45.

    Bierman PJ, Sweetenham JW, Loberiza FR, Jr., . Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin’s lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003;21:37443753.

    • Search Google Scholar
    • Export Citation
  • 46.

    Weisdorf D, Eapen M, Ruggeri A, . Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transplant 2014;20:816822.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Rashidi A, Hamadani M, Zhang MJ, . Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv 2019;3:18261836.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Meybodi MA, Cao W, Luznik L, . HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv 2019;3:25812585.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Bazarbachi A, Boumendil A, Finel H, . Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol 2019;188:745756.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Gluckman E, Broxmeyer HA, Auerbach AD, . Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:11741178.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 51.

    Wagner JE, Rosenthal J, Sweetman R, . Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996;88:795802.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Barker JN, Weisdorf DJ, DeFor TE, . Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:13431347.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Warlick ED, Peffault de Latour R, Shanley R, . Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type. Biol Blood Marrow Transplant 2015;21:357363.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Laughlin MJ, Eapen M, Rubinstein P, . Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004;351:22652275.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Marks DI, Woo KA, Zhong X, . Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica 2014;99:322328.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Rocha V, Labopin M, Sanz G, . Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004;351:22762285.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Othus M, Appelbaum FR, Petersdorf SH, . Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 2015;21:559564.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Yanada M, Matsuo K, Suzuki T, . Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006;106:26572663.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    de Witte T, Bowen D, Robin M, . Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood 2017;129:17531762.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 60.

    Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol 2003;40:5971.

  • 61.

    Kharfan-Dabaja MA, Kumar A, Hamadani M, . Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2016;22:21172125.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 62.

    Bruno B, Rotta M, Patriarca F, . Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009;113:33753382.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Shanavas M, Messner HA, Atenafu EG, . Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. Bone Marrow Transplant 2014;49:11621169.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Sureda A, Robinson S, Canals C, . Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455462.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 65.

    Rezvani AR, Norasetthada L, Gooley T, . Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008;143:395403.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Horowitz MM, Gale RP, Sondel PM, . Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555562.

  • 67.

    Corradini P, Dodero A, Zallio F, . Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004;22:21722176.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Weisdorf D, Zhang MJ, Arora M, . Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant 2012;18:17271733.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Muffly L, Pasquini MC, Martens M, . Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood 2017;130:11561164.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Ciurea SO, Shah MV, Saliba RM, . Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2018;24:12321236.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Sorror ML, Maris MB, Storb R, . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:29122919.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Sorror ML, Logan BR, Zhu X, . Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow Transplant research study. Biol Blood Marrow Transplant 2015;21:14791487.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    ElSawy M, Storer BE, Pulsipher MA, . Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol 2015;170:574583.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Saad A, Mahindra A, Zhang MJ, . Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2014;20:402408.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Berro M, Arbelbide JA, Rivas MM, . Hematopoietic cell transplantation-specific comorbidity index predicts morbidity and mortality in autologous stem cell transplantation. Biol Blood Marrow Transplant 2017;23:16461650.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Sorror ML, Storb RF, Sandmaier BM, . Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014;32:32493256.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood 2013;121:28542863.

  • 78.

    Foundation for the Accreditation of Cellular Therapy and Joint Accreditation Committee-ISCT and EBMT. FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, 7th Ed. Omaha, NE:;University of Nebraska Medical Center; 2017.

    • Search Google Scholar
    • Export Citation
  • 79.

    Przepiorka D, Weisdorf D, Martin P, . 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825828.

  • 80.

    Filipovich AH, Weisdorf D, Pavletic S, . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945956.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 81.

    Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood 2015;125:606615.

  • 82.

    Arai S, Arora M, Wang T, . Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2015;21:266274.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Jagasia M, Arora M, Flowers ME, . Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119:296307.

  • 84.

    Flowers ME, Inamoto Y, Carpenter PA, . Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011;117:32143219.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Jagasia MH, Greinix HT, Arora M, . National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 2015;21:389401.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 86.

    Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med 2017;377:21672179.

  • 87.

    Martin PJ, Rizzo JD, Wingard JR, . First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012;18:11501163.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 88.

    Ross WA, Ghosh S, Dekovich AA, . Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol 2008;103:982989.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Glucksberg H, Storb R, Fefer A, . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295304.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Rowlings PA, Przepiorka D, Klein JP, . IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997;97:855864.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Martino R, Romero P, Subirá M, . Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Bone Marrow Transplant 1999;24:283287.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    MacMillan ML, DeFor TE, Weisdorf DJ. What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol 2012;157:732741.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    MacMillan ML, Robin M, Harris AC, . A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant 2015;21:761767.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Harris AC, Young R, Devine S, . International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 2016;22:410.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 95.

    Schoemans HM, Lee SJ, Ferrara JL, . EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 2018;53:14011415.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Major-Monfried H, Renteria AS, Pawarode A, . MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood 2018;131:28462855.

  • 97.

    Ali AM, DiPersio JF, Schroeder MA. The role of biomarkers in the diagnosis and risk stratification of acute graft-versus-host disease: a systematic review. Biol Blood Marrow Transplant 2016;22:15521564.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Levine JE, Braun TM, Harris AC, . A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol 2015;2:e21e29.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Mielcarek M, Furlong T, Storer BE, . Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica 2015;100:842848.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    American Society for Transplantation and Cellular Therapy & Cell Therapy Transplant Canada. Choosing Wisely: Five Things Physicians and Patients Should Question. 2019. Accessed February 26, 2020. Available at: https://www.choosingwisely.org/societies/american-society-for-transplantation-and-cellular-therapy-and-cell-therapy-transplant-canada/

  • 101.

    Alousi AM, Weisdorf DJ, Logan BR, . Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009;114:511517.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Bolaños-Meade J, Logan BR, Alousi AM, . Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood 2014;124:32213227., quiz 3335.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Pidala J, Hamadani M, Dawson P, . Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood 2020;135:97107.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Jagasia M, Ali H, Schroeder MA, . Ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease: results from the phase 2 REACH1 trial. Biol Blood Marrow Transplant 2019;25(Suppl):S52.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 105.

    Pidala J, Kurland B, Chai X, . Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011;117:46514657.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Lee SJ, Wolff D, Kitko C, . Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant 2015;21:984999.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 107.

    Carpenter PA, Kitko CL, Elad S, . National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 2015;21:11671187.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 108.

    Shulman HM, Cardona DM, Greenson JK, . NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant 2015;21:589603.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 109.

    Paczesny S, Hakim FT, Pidala J, . National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 biomarker working group report. Biol Blood Marrow Transplant 2015;21:780792.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 110.

    Bergeron A, Chevret S, Granata A, . Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial. JAMA 2017;318:557566.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Miklos D, Cutler CS, Arora M, . Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 2017;130:22432250.

  • 112.

    MacDonald KPA, Betts BC, Couriel D. Emerging therapeutics for the control of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2018;24:1926.

  • 113.

    Pidala J, Anasetti C. Glucocorticoid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2010;16:15041518.

  • 114.

    U.S. Food and Drug Administration. Alemtuzumab Package Insert. 2001. Accessed January 14, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103948s5070lbl.pdf.

    • Export Citation
  • 115.

    Khouri IF, Albitar M, Saliba RM, . Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant 2004;33:833837.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Gómez-Almaguer D, Ruiz-Argüelles GJ, del Carmen Tarín-Arzaga L, . Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:1015.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Schnitzler M, Hasskarl J, Egger M, . Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009;15:910918.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Magenau JM, Goldstein SC, Peltier D, . α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood 2018;131:13721379.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Pye A, Turner AM. Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency. Expert Opin Investig Drugs 2019;28:891902.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Arai Y, Jo T, Matsui H, . Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymphoma 2017;58:18401848.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Alousi AM, Brammer JE, Saliba RM, . Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biol Blood Marrow Transplant 2015;21:906912.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Czerw T, Labopin M, Giebel S, . Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Cancer 2018;124:25232533.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Kröger N, Solano C, Wolschke C, . Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 2016;374:4353.

  • 124.

    Kumar A, Reljic T, Hamadani M, . Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant 2019;54:10941106.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Ziakas PD, Zervou FN, Zacharioudakis IM, . Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis. PLoS One 2014;9:e114735.

  • 126.

    U.S. Food and Drug Administration. Thymoglobulin Package Insert. 1998. Accessed February 28, 2020. Available at: https://www.fda.gov/media/74641/download

    • Export Citation
  • 127.

    U.S. Food and Drug Administration. Atgam Package Insert. 1981. Accessed February 28, 2020. Available at: https://www.fda.gov/media/78206/download

    • Export Citation
  • 128.

    MacMillan ML, Weisdorf DJ, Davies SM, . Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002;8:4046.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    McCaul KG, Nevill TJ, Barnett MJ, . Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000;9:367374.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Nishimoto M, Nakamae H, Koh H, . Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin. Exp Hematol 2015;43:177179.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Ali R, Ramdial J, Algaze S, . The role of anti-thymocyte globulin or alemtuzumab-based serotherapy in the prophylaxis and management of graft-versus-host disease. Biomedicines 2017;5:57.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 132.

    U.S. Food and Drug Administration. Basiliximab Package Insert. 1998. Accessed January 14, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/basnov051298lb.pdf

    • Export Citation
  • 133.

    Schmidt-Hieber M, Fietz T, Knauf W, . Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005;130:568574.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    U.S. Food and Drug Administration. Tacrolimus Package Insert. 1994. Accessed February 6, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050709s031lbl.pdf

    • Export Citation
  • 135.

    U.S. Food and Drug Administration. Cyclosporine Package Insert. 1983. Accessed February 6, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050573s035,050574s043,050625s049lbl.pdf

    • Export Citation
  • 136.

    Moiseev IS, Pirogova OV, Alyanski AL, . Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant 2016;22:10371042.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Kanda Y, Kobayashi T, Mori T, . A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. Bone Marrow Transplant 2016;51:103109.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Mielcarek M, Furlong T, O’Donnell PV, . Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood 2016;127:15021508.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Törlén J, Ringdén O, Garming-Legert K, . A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica 2016;101:14171425.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Al-Kadhimi Z, Gul Z, Abidi M, . Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention. Bone Marrow Transplant 2017;52:13041310.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 141.

    Cutler C, Logan B, Nakamura R, . Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014;124:13721377.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Gao L, Liu J, Zhang Y, . Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation. Leuk Res 2017;57:2736.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Deeg HJ, Loughran TP, Jr., Storb R, . Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985;40:162166.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    Kanamaru A, Takemoto Y, Kakishita E, . FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant 1995;15:885889.

    • Search Google Scholar
    • Export Citation
  • 145.

    Xhaard A, Launay M, Sicre de Fontbrune F, . A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor. Bone Marrow Transplant 2020;55:8692.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    U.S. Food and Drug Administration. Etanercept Package Insert. 1998. Accessed January 14, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103795s5569lbl.pdf

    • Export Citation
  • 147.

    Couriel D, Saliba R, Hicks K, . Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004;104:649654.

  • 148.

    Busca A, Locatelli F, Marmont F, . Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007;82:4552.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Abu-Dalle I, Reljic T, Nishihori T, . Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant 2014;20:16771686.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 150.

    Smith EP, Sniecinski I, Dagis AC, . Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transplant 1998;4:2737.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 151.

    Alcindor T, Gorgun G, Miller KB, . Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 2001;98:16221625.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Greinix HT, Knobler RM, Worel N, . The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006;91:405408.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 153.

    Sakellari I, Gavriilaki E, Batsis I, . Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single-center study. J Clin Apher 2018;33:654660.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 154.

    Zhang H, Chen R, Cheng J, . Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD. Patient Prefer Adherence 2015;9:105111.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 155.

    U.S. Food and Drug Administration. Infliximab Package Insert. 1998. Accessed January 29, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf

    • Export Citation
  • 156.

    Patriarca F, Sperotto A, Damiani D, . Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004;89:13521359.

  • 157.

    Yalniz FF, Hefazi M, McCullough K, . Safety and efficacy of infliximab therapy in the setting of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2017;23:14781484.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 158.

    Himmelfarb J, Sayegh MH, eds. Current and emerging maintenance immunosuppressive therapy. in Chronic Kidney Disease, Dialysis, and Transplantation, 3rd Ed. Philadelphia, PA: W.B. Saunders; 2010 . https://doi.org/10.1016/B978-1-4377-0987-2.00036-4

    • Search Google Scholar
    • Export Citation
  • 159.

    Hsieh A. mTOR: the master regulator. Cell 2012;149:955957.

  • 160.

    Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996;58:373395.

  • 161.

    Armand P, Kim HT, Sainvil MM, . The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol 2016;173:96104.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 162.

    Kornblit B, Maloney DG, Storer BE, . A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica 2014;99:16241631.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 163.

    Pidala J, Kim J, Alsina M, . Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica 2015;100:970977.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    Wang L, Gu Z, Zhai R, . The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. Transfusion 2015;55:21342141.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 165.

    Benito AI, Furlong T, Martin PJ, . Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001;72:19241929.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 166.

    Hoda D, Pidala J, Salgado-Vila N, . Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 2010;45:13471351.

  • 167.

    Ghez D, Rubio MT, Maillard N, . Rapamycin for refractory acute graft-versus-host disease. Transplantation 2009;88:10811087.

  • 168.

    Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85118.

  • 169.

    U.S. Food and Drug Administration. Mycophenolate Mofetil Package Insert. 1995. Accessed January 29, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050722s035,050723s035,050758s033,050759s041lbl.pdf

    • Export Citation
  • 170.

    Furlong T, Martin P, Flowers ME, . Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009;44:739748.

  • 171.

    Kim JG, Sohn SK, Kim DH, . Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004;73:5661.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 172.

    Pidala J, Kim J, Perkins J, . Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant 2010;45:919924.

  • 173.

    U.S. Food and Drug Administration. Pentostatin Package Insert. 2007. Accessed January 29, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020122s015lbl.pdf

    • Export Citation
  • 174.

    Ragon BK, Mehta RS, Gulbis AM, . Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 2018;53:315325.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 175.

    Schmitt T, Luft T, Hegenbart U, . Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. Bone Marrow Transplant 2011;46:580585.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 176.

    Pidala J, Kim J, Roman-Diaz J, . Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Ann Transplant 2010;15:2129.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Bolaños-Meade J, Jacobsohn DA, Margolis J, . Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005;23:26612668.

  • 178.

    Poi MJ, Hofmeister CC, Johnston JS, . Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clin Pharmacokinet 2013;52:705712.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 179.

    Jagasia M, Zeiser R, Arbushites M, . Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy 2018;10:391402.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 180.

    U.S. Food and Drug Administration. FDA approves ruxolitinib for acute graft-versus-host disease. 2019. Accessed January 24, 2020. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-acute-graft-versus-host-disease

    • Export Citation
  • 181.

    Zeiser R, Burchert A, Lengerke C, . Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015;29:20622068.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 182.

    U.S. Food and Drug Administration. Tocilizumab Package Insert. 2010. Accessed January 28, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf

    • Export Citation
  • 183.

    Imamura M, Hashino S, Kobayashi H, . Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant 1994;13:745751.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 184.

    Cavet J, Dickinson AM, Norden J, . Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001;98:15941600.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 185.

    Ganetsky A, Frey NV, Hexner EO, . Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplant 2019;54:212217.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 186.

    Gergis U, Arnason J, Yantiss R, . Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. J Clin Oncol 2010;28:e602e604.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 187.

    Yucebay F, Matthews C, Puto M, . Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience. Leuk Lymphoma 2019;60:22232229.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 188.

    Roddy JV, Haverkos BM, McBride A, . Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma 2016;57:8185.

  • 189.

    Drobyski WR, Pasquini M, Kovatovic K, . Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:18621868.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 190.

    Fløisand Y, Lazarevic VL, Maertens J, . Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review. Biol Blood Marrow Transplant 2019;25:720727.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 191.

    Danylesko I, Bukauskas A, Paulson M, . Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. Bone Marrow Transplant 2019;54:987993.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 192.

    Fløisand Y, Lundin KEA, Lazarevic V, . Targeting integrin alpha4beta7 in steroid-refractory intestinal graft-versus-host disease. Biol Blood Marrow Transplant 2017;23:172175.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 193.

    U.S. Food and Drug Administration. Natalizumab Package Insert. 2004. Accessed March 2, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125104s0576lbl.pdf

    • Export Citation
  • 194.

    U.S. Food and Drug Administration. Vedolizumab Package Insert. 2014. Accessed March 2, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf

    • Export Citation
  • 195.

    Nahas MR, Soiffer RJ, Kim HT, . Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood 2018;131:28362845.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 196.

    U.S. Food and Drug Administration. Abatacept Package Insert. 2005. Accessed January 29, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125118s171lbl.pdf

    • Export Citation
  • 197.

    Nikiforow S, Kim HT, Bindra B, . Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2013;19:804811.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 198.

    Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, Borjas-Almaguer OD, . Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. Haematologica 2012;97:717722.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 199.

    Tzakis AG, Abu-Elmagd K, Fung JJ, . FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc 1991;23:32253227.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 200.

    Carnevale-Schianca F, Martin P, Sullivan K, . Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000;6:613620.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 201.

    Yanik GA, Mineishi S, Levine JE, . Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2012;18:10441054.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 202.

    Flowers ME, Apperley JF, van Besien K, . A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008;112:26672674.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 203.

    Couriel DR, Hosing C, Saliba R, . Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006;107:30743080.

  • 204.

    Malik MI, Litzow M, Hogan W, . Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res 2014;49:100106.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 205.

    U.S. Food and Drug Administration. Hydroxychloroquine Package Insert. 1955. Accessed January 31, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf

    • Export Citation
  • 206.

    Wolff D, Schleuning M, von Harsdorf S, . Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:117.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 207.

    Gilman AL, Chan KW, Mogul A, . Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000;6(3, 3A)327334.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 208.

    Navajas EV, Krema H, Hammoudi DS, . Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. Can J Ophthalmol 2015;50:442450.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 209.

    Dubovsky JA, Beckwith KA, Natarajan G, . Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013;122:25392549.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 210.

    U.S. Food and Drug Administration. Ibrutnib Package Insert. 2013. Accessed February 3, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210563s000lbl.pdf

    • Export Citation
  • 211.

    Waller EK, Miklos D, Cutler C, . Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b/2 study. Biol Blood Marrow Transplant 2019;25:20022007.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 212.

    U.S. Food and Drug Administration. Imatinib Package Insert. 2001. Accessed February 3, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf

    • Export Citation
  • 213.

    Baird K, Comis LE, Joe GO, . Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant 2015;21:10831090.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 214.

    Chen GL, Arai S, Flowers ME, . A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood 2011;118:40704078.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 215.

    Arai S, Pidala J, Pusic I, . A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res 2016;22:319327.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 216.

    Olivieri A, Cimminiello M, Corradini P, . Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood 2013;122:41114118.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 217.

    Koreth J, Kim HT, Jones KT, . Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood 2016;128:130137.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 218.

    Koreth J, Matsuoka K, Kim HT, . Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:20552066.

  • 219.

    Whangbo JS, Kim HT, Mirkovic N, . Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv 2019;3:25502561.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 220.

    U.S. Food and Drug Administration. Methotrexate Package Insert. 1972. Accessed February 4, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011719s117lbl.pdf

    • Export Citation
  • 221.

    Giaccone L, Martin P, Carpenter P, . Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant 2005;36:337341.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 222.

    de Lavallade H, Mohty M, Faucher C, . Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica 2006;91:14381440.

    • Search Google Scholar
    • Export Citation
  • 223.

    Huang XJ, Jiang Q, Chen H, . Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005;36:343348.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 224.

    Couriel DR, Saliba R, Escalón MP, . Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005;130:409417.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 225.

    Jurado M, Vallejo C, Pérez-Simón JA, . Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007;13:701706.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 226.

    Lutz M, Kapp M, Einsele H, . Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus. Clin Transplant 2014;28:14101415.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 227.

    Mielke S, Lutz M, Schmidhuber J, . Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis. Bone Marrow Transplant 2014;49:14121418.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 228.

    Lopez F, Parker P, Nademanee A, . Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:307313.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 229.

    U.S. Food and Drug Administration. Rituximab Package Insert. 1997. Accessed February 5, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf

    • Export Citation
  • 230.

    Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, . Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009;15:10051013.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 231.

    Modi B, Hernandez-Henderson M, Yang D, . Ruxolitinib as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2019;25:265269.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 232.

    Khoury HJ, Langston AA, Kota VK, . Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplant 2018;53:826831.